who is developing retatrutide Demand for Unapproved Weight-Loss Drug Surges on Social Media Retatrutide UK 2026: Phase 3

Cachexia Sarcopenia Muscle 15 (3), 10721083

Loperamide (Imodium) works for acute episodes but should not become a daily dependency

You will also need to meet specific criteria before a doctor will approve it for you

R., Burns, S

Underwriters are also getting better at detecting GLP-1 use through: Prescription databases Medical records requests Follow-up health questionnaires What This Means for Your Clients If currently on GLP-1 medications: Expect questions about medication use and duration Be prepared for potentially higher rates despite current health improvements Consider timing of application if they've been stable on medication for an extended period If recently stopped GLP-1 medications: Underwriters may view recent discontinuation as a risk factor Weight regain could further complicate the application process Medical follow-up showing sustained health improvements may help If planning to start GLP-1 medications: Understand that future applications may be affected by medication use Industry Trends to Watch Some forward-thinking insurance companies are exploring partnerships with GLP-1 providers to improve medication adherence

The CVOT results for the oral version of semaglutide (Rybelsus) are pending, with results expected soon